These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis. Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Pringsheim T; Steeves T Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404 [TBL] [Abstract][Full Text] [Related]
9. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis. Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025 [TBL] [Abstract][Full Text] [Related]
10. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. May DE; Kratochvil CJ Drugs; 2010; 70(1):15-40. PubMed ID: 20030423 [TBL] [Abstract][Full Text] [Related]
11. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder. Martinez-Raga J; Knecht C; Szerman N; Martinez MI CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939 [TBL] [Abstract][Full Text] [Related]
12. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]
13. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Garnock-Jones KP; Keating GM Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. Wigal SB CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975 [TBL] [Abstract][Full Text] [Related]
16. The potential for misuse and abuse of medications in ADHD: a review. Clemow DB; Walker DJ Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651 [TBL] [Abstract][Full Text] [Related]
17. Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis. Pan PY; Jonsson U; Şahpazoğlu Çakmak SS; Häge A; Hohmann S; Nobel Norrman H; Buitelaar JK; Banaschewski T; Cortese S; Coghill D; Bölte S Psychol Med; 2022 Jan; 52(1):14-25. PubMed ID: 34635194 [TBL] [Abstract][Full Text] [Related]